Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENERGY 2: INZ-701 in infants with ENPP1 deficiency
2024-512991-36-00Phase 3Completed
- Sponsor
- Inozyme Pharma
- Start
- Oct 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of INZ-701 in ENPP1 deficiency and generalized arterial calcification of infancy (GACI), sponsored by Inozyme Pharma. Primary endpoints: Change from baseline in plasma PPi concentration through Week 52 and Overall survival through Week 52. Started Oct 2024; status: completed.
02
Drugs
INZ-701
03
Conditions
ENPP1 deficiencygeneralized arterial calcification of infancy (GACI)
Beyond the preview
Go deeper on 2024-512991-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512991-36-00.